ArticleJournal of molecular histology2026
HMGB1 promotes intracranial aneurysm progression by regulating vascular smooth muscle cell phenotypic switching and ferroptosis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From hemodynamic stress to inflammatory wall remodeling in intracranial aneurysms.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Phenotypic switching in vascular smooth muscle cells (VSMCs) is key to the formation and progression of intracranial aneurysms (IAs). High-mobility group box 1 (HMGB1), a damage-associated molecule, significantly influences the progression of various diseases. Ferroptosis is an iron-dependent cell death process that is controlled by extensive membrane damage induced by lipid peroxidation. However, few studies have investigated the associations between VSMCs, HMGB1, ferroptosis, and IAs. To analyze the associations between VSMCs, HMGB1, ferroptosis, and IAs, we collected human tissue and blood samples, established an oxidative damage model in VSMCs induced using hydrogen peroxide, and analyzed the effects of interventions related to ferroptosis and HMGB1 on VSMC phenotypic changes in vitro. We measured ferroptosis levels, proliferation, migration capacity, and inflammatory molecule expression in VSMCs. In addition, we analyzed the nuclear-cytoplasmic translocation of HMGB1 and the nuclear factor κ light chain-enhancer of activated B cells (NF-κB) protein subunit p65. Then, we investigated the effects of HMGB1 inhibition on IA formation and progression in an elastase-induced rat model. Clinical experiments using human samples confirmed significant correlations between VSMC phenotypic switching, HMGB1, ferroptosis, and IAs. HMGB1 was activated and underwent translocation from the nucleus to the cytoplasm under oxidative stress conditions. By binding to TLR4, HMGB1 activated the NF-κB p65 pathway, promoted NF-κB p65 nuclear translocation, and induced inflammatory responses and ferroptosis, thereby mediating VSMC phenotypic switching. In animal studies, HMGB1 inhibition markedly reduced IA formation and progression. HMGB1 regulates VSMC phenotypic switching and contributes to the development of IAs by mediating ferroptosis.
Indexed as
Identifiers
42257786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.